Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors

被引：0

作者：

Heymach, John ^{[1
]}

Yamamoto, Noboru ^{[2
]}

Opdam, Frans ^{[3
]}

Barve, Minal ^{[4
]}

Tu, Hai-Yan ^{[5
]}

Wu, Yi-Long ^{[5
]}

Schroeter, Lukas ^{[6
]}

Sadrolhefazi, Behbood ^{[7
]}

Serra, Josep ^{[8
]}

Yoh, Kiyotaka ^{[9
]}

Berz, David ^{[10
]}

机构：

[1] Univ Texas Houston, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[2] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[3] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands

[4] Mary Crowley Canc Res, Dallas, TX USA

[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[8] 8 Boehringer Ingelheim Espana SA, Barcelona, Spain

[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[10] Valkyrie Clin Trials, Los Angeles, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA01.01

引用

页码：E1 / E1

页数：1